Erratum: HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome (Cardiovasc Res (2013) 99 (44-54) DOI: 10.1093/cvr/cvt070);HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome

Cardiovascular Research

Volumn 99, Issue 1, 2013, Pages 44-54

  Hermida, Nerea ^a   Markl, Andreas ^a   Hamelet, Julien ^a   Van Assche, Tim ^a   Vanderper, Annelies ^b   Herijgers, Paul ^b   Van Bilsen, Marc ^c   Hilfiker Kleiner, Denise ^d   Noppe, Gauthier ^a   Beauloye, Christophe ^a,e   Horman, Sandrine ^a,e   Balligand, Jean Luc ^a,e  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

AMPK; Diastolic dysfunction; Metabolic syndrome; Myocardial fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEPTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PLACEBO; ROSUVASTATIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL MIGRATION; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DRUG MECHANISM; ECHOCARDIOGRAPHY; FIBROBLAST; GENETIC TRANSFECTION; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART OUTPUT; IN VITRO STUDY; IN VIVO STUDY; METABOLIC SYNDROME X; MORPHOMETRICS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 84879358476     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvaa180     Document Type: Erratum

References (47)

1. de las FL, Brown AL, Mathews SJ, Waggoner AD, Soto PF, Gropler RJ et al. Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass. Eur Heart J 2007;28:553-559 (Pubitemid 47355514)
2. Grandi AM, Maresca AM, Giudici E, Laurita E, Marchesi C, Solbiati F et al. Metabolic syndrome and morphofunctional characteristics of the left ventricle in clinically hypertensive nondiabetic subjects. Am J Hypertens 2006;19:199-205 (Pubitemid 43350174)
3. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007;115:888-895 (Pubitemid 46294729)
4. Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989;64: 1041-1050 (Pubitemid 19155774)
5. Eghbali M, Weber KT. Collagen and the myocardium: fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its regression. Mol Cell Biochem 1990; 96:1-14 (Pubitemid 20224147)
6. Trackman PC. Diverse biological functions of extracellular collagen processing enzymes. J Cell Biochem 2005;96:927-937 (Pubitemid 41688719)
7. Adar R, Kessler E, Goldberg B. Evidence for a protein that enhances the activity of type I procollagen C-proteinase. Coll Relat Res 1986;6:267-277
8. Kagan HM, Trackman PC. Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol 1991;5:206-210
9. Lopez B, Querejeta R, Gonzalez A, Beaumont J, Larman M, Diez J. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009;53:236-242
10. Lopez B, Gonzalez A, Diez J. Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis. Curr Opin Nephrol Hypertens 2004;13: 197-204 (Pubitemid 38373142)
11. LaRosa JC, Deedwania PC, Shepherd J, Wenger NK, Greten H, DeMicco DA et al. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol 2010;105:283-287
12. Gomez-Garre D, Gonzalez-Rubio ML, Munoz-Pacheco P, Caro-Vadillo A, Aragoncillo P, Fernandez-Cruz A. Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction. Eur J Heart Fail 2010;12:903-912
13. Indolfi C, Di LE, Perrino C, Stingone AM, Curcio A, Torella D et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 2002;106: 2118-2124 (Pubitemid 35192819)
14. Meyer-Ter-Vehn T, Katzenberger B, Han H, Grehn F, Schlunck G. Lovastatin inhibits TGF-beta-induced myofibroblast transdifferentiation in human tendon fibroblasts. Invest Ophthalmol Vis Sci 2008;49:3955-3960
15. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45: 89-118 (Pubitemid 40261799)
16. Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM et al. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 2011;124: 1107-1117
17. Adam O, Neuberger HR, Bohm M, Laufs U. Prevention of atrial fibrillation with 3- hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation 2008;118: 1285-1293
18. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE, 3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003;108:1368-1374 (Pubitemid 37174416)
19. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22:300-305 (Pubitemid 34127043)
20. Du J, Guan T, Zhang H, Xia Y, Liu F, Zhang Y. Inhibitory crosstalk between ERK and AMPK in the growth and proliferation of cardiac fibroblasts. Biochem Biophys Res Commun 2008;368:402-407
21. Handy JA, Saxena NK, Fu P, Lin S, Mells JE, Gupta NA et al. Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3). J Cell Biochem 2010;110:1195-1207
22. Zhang P, Hu X, Xu X, Fassett J, Zhu G, Viollet B et al. AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 2008;52:918-924
23. Wong AK, Howie J, Petrie JR, Lang CC. AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond) 2009;116: 607-620
24. Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006;114:2655-2662 (Pubitemid 44967349)
25. Kou R, Sartoretto J, Michel T. Regulation of Rac1 by simvastatin in endothelial cells: differential roles of AMP-activated protein kinase and calmodulin-dependent kinase kinase-beta. J Biol Chem 2009;284:14734-14743
26. Van den Bergh A, Vanderper A, Vangheluwe P, Desjardins F, Nevelsteen I, Verreth W et al. Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. Cardiovasc Res 2008;77:371-379 (Pubitemid 351197628)
27. Verreth W, De KD, Pelat M, Verhamme P, Ganame J, Bielicki JK et al. Weight-loss-associated induction of peroxisome proliferator-activated receptoralpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulinresistant mice. Circulation 2004;110:3259-3269 (Pubitemid 39525075)
28. Penjaskovic D, Sakac D, Dejanovic J, Zec R, Zec PN, Stojsic MA. Left ventricular diastolic dysfunction in patients with metabolic syndrome. Med Pregl 2012;65:18-22
29. Ingelsson E, Arnlov J, Lind L, Sundstrom J. Metabolic syndrome and risk for heart failure in middle-aged men. Heart 2006;92:1409-1413 (Pubitemid 44578829)
30. Sciarretta S, Ferrucci A, Ciavarella GM, De PP, Venturelli V, Tocci G et al. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens 2007;20:784-791 (Pubitemid 46951019)
31. Hayden MR, Chowdhury N, Govindarajan G, Karuparthi PR, Habibi J, Sowers Jr. Myocardial myocyte remodeling and fibrosis in the cardiometabolic syndrome. J Cardiometab Syndr 2006;1:326-333
32. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009;119: 131-138
33. Desjardins F, Sekkali B, Verreth W, Pelat M, De KD, Mertens A et al. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Eur Heart J 2008;29:128-137
34. Sirker A, Zhang M, Murdoch C, Shah AM. Involvement of NADPH oxidases in cardiac remodelling and heart failure. Am J Nephrol 2007;27:649-660 (Pubitemid 350014953)
35. Maack C, Kartes T, Kilter H, Schafers HJ, Nickenig G, Bohm M et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003;108: 1567-1574 (Pubitemid 37187782)
36. Verreth W, De KD, Davey PC, Geeraert B, Mertens A, Herregods MC et al. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. Br J Pharmacol 2007;151:347-355 (Pubitemid 46842672)
37. Koitabashi N, Danner T, Zaiman AL, Pinto YM, Rowell J, Mankowski J et al. Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload. J Clin Invest 2011;121:2301-2312
38. Lenski M, Kazakov A, Marx N, Bohm M, Laufs U. Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol 2011;51:906-918
39. Viollet B, Athea Y, Mounier R, Guigas B, Zarrinpashneh E, Horman S et al. AMPK: lessons from transgenic and knockout animals. Front Biosci 2009;14:19-44
40. Gul R, Demarco VG, Sowers JR, Whaley-Connell A, Pulakat L. Regulation of overnutrition-induced cardiac inflammatory mechanisms. Cardiorenal Med 2012;2: 225-233
41. van den Brom CE, Bosmans JW, Vlasblom R, Handoko LM, Huisman MC, Lubberink M et al. Diabetic cardiomyopathy in Zucker diabetic fatty rats: the forgotten right ventricle. Cardiovasc Diabetol 2010;9:25
42. Laufs U, Kilter H, Konkol C,Wassmann S, Bohm M, Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002;53:911-920 (Pubitemid 34261029)
43. Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, Shimokawa H. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J 2009;73:361-370
44. Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J et al. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 2008;58:2553-2564
45. Lakshmanan AP, Harima M, Sukumaran V, Soetikno V, Thandavarayan RA, Suzuki K et al. Modulation of AT-1R/AMPK-MAPK cascade plays crucial role for the pathogenesis of diabetic cardiomyopathy in transgenic type 2 diabetic (Spontaneous Diabetic Torii) rats. Biochem Pharmacol 2012;83:653-660
46. Gormand A, Henriksson E, Stro?m K, Jensen TE, Sakamoto K, Go?ransson O. Regulation of AMP-activated protein kinase by LKB1 and CaMKK in adipocytes. J Cell Biochem 2011;112:1364-1375
47. Su DF. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies. Curr Opin Cardiol 2006;21:486-491. Wallonie-Bruxelle